Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies
Various mechanisms with a complex integrating paradigm have been implicated in diabetic complications. The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic...
Gespeichert in:
| Veröffentlicht in: | Pharmacological reports 2014-10, Vol.66 (5), p.799-803 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 803 |
|---|---|
| container_issue | 5 |
| container_start_page | 799 |
| container_title | Pharmacological reports |
| container_volume | 66 |
| creator | Ciddi, Veeresham Dodda, Dilip |
| description | Various mechanisms with a complex integrating paradigm have been implicated in diabetic complications. The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy.
RSV was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit formation of AGEs. Anticataract activity of RSV was demonstrated using sugar induced lens opacity model in isolated cattle lens. Furthermore the involvement of RSV in streptozotocin-induced diabetic nephropathy was investigated by assessing the key markers of kidney function along with the formation of AGEs. The potent AR inhibitor, fidarestat was as a standard.
RSV exhibited inhibitory activity against RLAR and RKAR with IC50 values of 4.99μg/ml (21.9μM) and 5.49μg/ml (24.5μM), respectively. It also showed a significant inhibition of AGEs formation in vitro. In sugar-induced lens opacity model, RSV displayed a significant protective effect preventing opacification and formation of polyols in cattle lens. RSV significantly improved glycaemic status and renal function in diabetic rats with a significant decrease in the formation of AGEs in the kidneys.
The results obtained in this study underline the potential of RSV as a possible therapeutic agent against long-term diabetic complications. |
| doi_str_mv | 10.1016/j.pharep.2014.04.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1555625935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1734114014001625</els_id><sourcerecordid>1555625935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-dd419b84d967a3875c0028ffc51b10513b6717dd02d9c190d9234d5812f31e503</originalsourceid><addsrcrecordid>eNqFkMFq3DAQhkVpSDZp3qAUHXvxViNLttVDoYQ2DQR6SW4FIUvjRovXciXZkLevFqc9tjCgw3z_L-Yj5C2wPTBoPhz285OJOO85A7FnZVjziuw4V6qSTSdekx20tagABLsglykdGBPAa3lOLrgEoVRX78iPhyeMZsYle0vnkHHK3ow0DDRiWssqxzBSP1HnTY8nyIbjPHprsg9T-kjvJrr6AlEzuRO3-jXQlBfnMb0hZ4MZE16_vFfk8euXh5tv1f3327ubz_eVFa3IlXMCVN8Jp5rW1F0rLWO8GwYroQcmoe6bFlrnGHfKgmJO8Vo42QEfakDJ6ivyfuudY_i1YMr66JPFcTQThiVpkFI2XKpaFlRsqI0hpYiDnqM_mvisgemTV33Qm1d98qpZGdaU2LuXH5b-iO5v6I_IAsgNSGU1_cSoD2GJU7n6f8WfthwWP6svuWQ9Thadj2izdsH_u-A35Syc2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1555625935</pqid></control><display><type>article</type><title>Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ciddi, Veeresham ; Dodda, Dilip</creator><creatorcontrib>Ciddi, Veeresham ; Dodda, Dilip</creatorcontrib><description>Various mechanisms with a complex integrating paradigm have been implicated in diabetic complications. The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy.
RSV was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit formation of AGEs. Anticataract activity of RSV was demonstrated using sugar induced lens opacity model in isolated cattle lens. Furthermore the involvement of RSV in streptozotocin-induced diabetic nephropathy was investigated by assessing the key markers of kidney function along with the formation of AGEs. The potent AR inhibitor, fidarestat was as a standard.
RSV exhibited inhibitory activity against RLAR and RKAR with IC50 values of 4.99μg/ml (21.9μM) and 5.49μg/ml (24.5μM), respectively. It also showed a significant inhibition of AGEs formation in vitro. In sugar-induced lens opacity model, RSV displayed a significant protective effect preventing opacification and formation of polyols in cattle lens. RSV significantly improved glycaemic status and renal function in diabetic rats with a significant decrease in the formation of AGEs in the kidneys.
The results obtained in this study underline the potential of RSV as a possible therapeutic agent against long-term diabetic complications.</description><identifier>ISSN: 1734-1140</identifier><identifier>EISSN: 2299-5684</identifier><identifier>DOI: 10.1016/j.pharep.2014.04.006</identifier><identifier>PMID: 25149983</identifier><language>eng</language><publisher>Cham: Elsevier Urban & Partner Sp. z o.o</publisher><subject>Advanced glycation end products ; Aldehyde Reductase - antagonists & inhibitors ; Aldose reductase inhibition ; Animals ; Cataract ; Cataract - etiology ; Cataract - prevention & control ; Cattle ; Diabetes Mellitus, Experimental - complications ; Diabetes Mellitus, Experimental - drug therapy ; Diabetic Nephropathies - prevention & control ; Diabetic nephropathy ; Disease Models, Animal ; Drug Safety and Pharmacovigilance ; Glycation End Products, Advanced - antagonists & inhibitors ; Imidazolidines - pharmacology ; Inhibitory Concentration 50 ; Kidney Function Tests ; Lens, Crystalline - drug effects ; Lens, Crystalline - pathology ; Male ; Original Research Article ; Pharmacotherapy ; Pharmacy ; Rats ; Rats, Wistar ; Resveratrol ; Stilbenes - administration & dosage ; Stilbenes - pharmacology ; Streptozocin</subject><ispartof>Pharmacological reports, 2014-10, Vol.66 (5), p.799-803</ispartof><rights>2014 Institute of Pharmacology, Polish Academy of Sciences</rights><rights>Maj Institute of Pharmacology, Polish Academy of Sciences 2014</rights><rights>Copyright © 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-dd419b84d967a3875c0028ffc51b10513b6717dd02d9c190d9234d5812f31e503</citedby><cites>FETCH-LOGICAL-c474t-dd419b84d967a3875c0028ffc51b10513b6717dd02d9c190d9234d5812f31e503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1016/j.pharep.2014.04.006$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1016/j.pharep.2014.04.006$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25149983$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ciddi, Veeresham</creatorcontrib><creatorcontrib>Dodda, Dilip</creatorcontrib><title>Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies</title><title>Pharmacological reports</title><addtitle>Pharmacol. Rep</addtitle><addtitle>Pharmacol Rep</addtitle><description>Various mechanisms with a complex integrating paradigm have been implicated in diabetic complications. The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy.
RSV was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit formation of AGEs. Anticataract activity of RSV was demonstrated using sugar induced lens opacity model in isolated cattle lens. Furthermore the involvement of RSV in streptozotocin-induced diabetic nephropathy was investigated by assessing the key markers of kidney function along with the formation of AGEs. The potent AR inhibitor, fidarestat was as a standard.
RSV exhibited inhibitory activity against RLAR and RKAR with IC50 values of 4.99μg/ml (21.9μM) and 5.49μg/ml (24.5μM), respectively. It also showed a significant inhibition of AGEs formation in vitro. In sugar-induced lens opacity model, RSV displayed a significant protective effect preventing opacification and formation of polyols in cattle lens. RSV significantly improved glycaemic status and renal function in diabetic rats with a significant decrease in the formation of AGEs in the kidneys.
The results obtained in this study underline the potential of RSV as a possible therapeutic agent against long-term diabetic complications.</description><subject>Advanced glycation end products</subject><subject>Aldehyde Reductase - antagonists & inhibitors</subject><subject>Aldose reductase inhibition</subject><subject>Animals</subject><subject>Cataract</subject><subject>Cataract - etiology</subject><subject>Cataract - prevention & control</subject><subject>Cattle</subject><subject>Diabetes Mellitus, Experimental - complications</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetic Nephropathies - prevention & control</subject><subject>Diabetic nephropathy</subject><subject>Disease Models, Animal</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Glycation End Products, Advanced - antagonists & inhibitors</subject><subject>Imidazolidines - pharmacology</subject><subject>Inhibitory Concentration 50</subject><subject>Kidney Function Tests</subject><subject>Lens, Crystalline - drug effects</subject><subject>Lens, Crystalline - pathology</subject><subject>Male</subject><subject>Original Research Article</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Resveratrol</subject><subject>Stilbenes - administration & dosage</subject><subject>Stilbenes - pharmacology</subject><subject>Streptozocin</subject><issn>1734-1140</issn><issn>2299-5684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFq3DAQhkVpSDZp3qAUHXvxViNLttVDoYQ2DQR6SW4FIUvjRovXciXZkLevFqc9tjCgw3z_L-Yj5C2wPTBoPhz285OJOO85A7FnZVjziuw4V6qSTSdekx20tagABLsglykdGBPAa3lOLrgEoVRX78iPhyeMZsYle0vnkHHK3ow0DDRiWssqxzBSP1HnTY8nyIbjPHprsg9T-kjvJrr6AlEzuRO3-jXQlBfnMb0hZ4MZE16_vFfk8euXh5tv1f3327ubz_eVFa3IlXMCVN8Jp5rW1F0rLWO8GwYroQcmoe6bFlrnGHfKgmJO8Vo42QEfakDJ6ivyfuudY_i1YMr66JPFcTQThiVpkFI2XKpaFlRsqI0hpYiDnqM_mvisgemTV33Qm1d98qpZGdaU2LuXH5b-iO5v6I_IAsgNSGU1_cSoD2GJU7n6f8WfthwWP6svuWQ9Thadj2izdsH_u-A35Syc2w</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Ciddi, Veeresham</creator><creator>Dodda, Dilip</creator><general>Elsevier Urban & Partner Sp. z o.o</general><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141001</creationdate><title>Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies</title><author>Ciddi, Veeresham ; Dodda, Dilip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-dd419b84d967a3875c0028ffc51b10513b6717dd02d9c190d9234d5812f31e503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Advanced glycation end products</topic><topic>Aldehyde Reductase - antagonists & inhibitors</topic><topic>Aldose reductase inhibition</topic><topic>Animals</topic><topic>Cataract</topic><topic>Cataract - etiology</topic><topic>Cataract - prevention & control</topic><topic>Cattle</topic><topic>Diabetes Mellitus, Experimental - complications</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetic Nephropathies - prevention & control</topic><topic>Diabetic nephropathy</topic><topic>Disease Models, Animal</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Glycation End Products, Advanced - antagonists & inhibitors</topic><topic>Imidazolidines - pharmacology</topic><topic>Inhibitory Concentration 50</topic><topic>Kidney Function Tests</topic><topic>Lens, Crystalline - drug effects</topic><topic>Lens, Crystalline - pathology</topic><topic>Male</topic><topic>Original Research Article</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Resveratrol</topic><topic>Stilbenes - administration & dosage</topic><topic>Stilbenes - pharmacology</topic><topic>Streptozocin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ciddi, Veeresham</creatorcontrib><creatorcontrib>Dodda, Dilip</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ciddi, Veeresham</au><au>Dodda, Dilip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies</atitle><jtitle>Pharmacological reports</jtitle><stitle>Pharmacol. Rep</stitle><addtitle>Pharmacol Rep</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>66</volume><issue>5</issue><spage>799</spage><epage>803</epage><pages>799-803</pages><issn>1734-1140</issn><eissn>2299-5684</eissn><abstract>Various mechanisms with a complex integrating paradigm have been implicated in diabetic complications. The present study was aimed to evaluate the aldose reductase (AR) and advanced glycation end products (AGEs) inhibitory activity of resveratrol (RSV) and its potential in the treatment of diabetic complications such as cataract and nephropathy.
RSV was studied for its inhibitory activity against rat lens AR (RLAR) and rat kidney AR (RKAR) in vitro along with its ability to inhibit formation of AGEs. Anticataract activity of RSV was demonstrated using sugar induced lens opacity model in isolated cattle lens. Furthermore the involvement of RSV in streptozotocin-induced diabetic nephropathy was investigated by assessing the key markers of kidney function along with the formation of AGEs. The potent AR inhibitor, fidarestat was as a standard.
RSV exhibited inhibitory activity against RLAR and RKAR with IC50 values of 4.99μg/ml (21.9μM) and 5.49μg/ml (24.5μM), respectively. It also showed a significant inhibition of AGEs formation in vitro. In sugar-induced lens opacity model, RSV displayed a significant protective effect preventing opacification and formation of polyols in cattle lens. RSV significantly improved glycaemic status and renal function in diabetic rats with a significant decrease in the formation of AGEs in the kidneys.
The results obtained in this study underline the potential of RSV as a possible therapeutic agent against long-term diabetic complications.</abstract><cop>Cham</cop><pub>Elsevier Urban & Partner Sp. z o.o</pub><pmid>25149983</pmid><doi>10.1016/j.pharep.2014.04.006</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1734-1140 |
| ispartof | Pharmacological reports, 2014-10, Vol.66 (5), p.799-803 |
| issn | 1734-1140 2299-5684 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1555625935 |
| source | MEDLINE; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings |
| subjects | Advanced glycation end products Aldehyde Reductase - antagonists & inhibitors Aldose reductase inhibition Animals Cataract Cataract - etiology Cataract - prevention & control Cattle Diabetes Mellitus, Experimental - complications Diabetes Mellitus, Experimental - drug therapy Diabetic Nephropathies - prevention & control Diabetic nephropathy Disease Models, Animal Drug Safety and Pharmacovigilance Glycation End Products, Advanced - antagonists & inhibitors Imidazolidines - pharmacology Inhibitory Concentration 50 Kidney Function Tests Lens, Crystalline - drug effects Lens, Crystalline - pathology Male Original Research Article Pharmacotherapy Pharmacy Rats Rats, Wistar Resveratrol Stilbenes - administration & dosage Stilbenes - pharmacology Streptozocin |
| title | Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T04%3A52%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20potential%20of%20resveratrol%20in%20diabetic%20complications:%20In%20vitro%20and%20in%20vivo%20studies&rft.jtitle=Pharmacological%20reports&rft.au=Ciddi,%20Veeresham&rft.date=2014-10-01&rft.volume=66&rft.issue=5&rft.spage=799&rft.epage=803&rft.pages=799-803&rft.issn=1734-1140&rft.eissn=2299-5684&rft_id=info:doi/10.1016/j.pharep.2014.04.006&rft_dat=%3Cproquest_cross%3E1555625935%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1555625935&rft_id=info:pmid/25149983&rft_els_id=S1734114014001625&rfr_iscdi=true |